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Introduction
Chronic recurrent multifocal osteomyelitis (CRMO) is
an autoinflammatory bone disease of unknown etiology.
Clinically, the disease is characterized by the insidious
onset of local pain and swelling in affected bones. Its
course is one of intermittent periods of exacerbation
and remission with successive bones affected.CRMO
most commonly affects the metaphysis of long bones,
especially the tibia, femur, and clavicle. The spine, pelvis,
ribs, sternum, and mandible may also be affected.
Although lesions are mostly multiple, patients may present
with a single symptomatic focus. Treatment in CRMO is
empiric, since placebo controlled randomized trials have
not been performed.
Objectives
To describe the outcome of CRMO patients treated with
neridronate.
Methods
We report 8 patients (3 M.5 F, mean age 8ys) Median age
of first CRMO symptoms was 6.3 years (range 5-13). The
more affected sites were the metaphysis of the long bones,
pelvis and coxofemoral joints.
Results
Seven patients failed to respond to NSAIDs therapy. Two
patients received corticosteroids, without clinical disease
remission. Four patients received neridronate (2mg/kg
body weight every 3 months for 1 year), all with good
clinical response and induction of clinical remission. After
a median follow-up period of 3.2 years (range 1-5), three
patients are clinically asymptomatic and one patient
required another 6 months course to reach and sustain
remission.
Conclusion
The treatment of CRMO is not standardized. Bisphospho-
nate therapy can be of benefit to patients with relapsing
symptoms. Randomized controlled multicentric trials
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